Rapid Communication|Articles in Press, 103702

Nephrolithiasis in Two Patients on Iron Chelation Therapy: A Case Report


      Drug-induced nephrolithiasis can arise from insoluble components within medications or crystallization of metabolites due to changes in metabolism and urinary pH. The connection between drugs utilized for iron chelation therapy (ICT) and nephrolithiasis is not well understood. In this report, we describe two pediatric patients diagnosed with nephrolithiasis while undergoing treatment with the chelating agents deferasirox, deferiprone, and deferoxamine for iron overload secondary to repeat blood transfusion


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Daudon M.
        • Frochot V.
        • Bazin D.
        • Jungers P.
        Drug-induced kidney stones and crystalline nephropathy: Pathophysiology, prevention and treatment.
        Drugs. 2018; 78: 163-201
        • Coates T.D.
        Physiology and pathophysiology of iron in hemoglobin-associated diseases.
        Free Radic Biol Med. 2014; 72: 23-40
        • Sighinolfi M.C.
        • Eissa A.
        • Bevilacqua L.
        • Zoeir A.
        • Ciarlariello S.
        • Morini E.
        • et al.
        Drug-induced urolithiasis in pediatric patients.
        Paediatr Drugs. 2019; 21: 323-344
        • Ishikawa N.
        • Tani H.
        • Kobayashi Y.
        • Kato A.
        • Kobayashi M.
        High incidence of renal stones in severely disabled children with epilepsy treated with topiramate.
        Neuropediatrics. 2019; 50: 160-163
        • Wong P.
        • Polkinghorne K.
        • Kerr P.G.
        • Doery J.C.
        • Gillespie M.T.
        • Larmour I.
        • et al.
        Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria.
        Bone. 2016; 85 ( 55-58
        • Tanous O.
        • Azulay Y.
        • Halevy R.
        • Dujovny T.
        • Swartz N.
        • Colodner R.
        • et al.
        Renal function in β-thalassemia major patients treated with two different iron-chelation regimes.
        BMC Nephrol. 2021; 22 (https://doi): 418
        • Yacobovich J.
        • Krause I.
        • Semo-Oz R.
        • Tamary H.
        Nephrolithiasis in transfusion-dependent pediatric patients.
        Blood. 2014; 124: 4895
        • Efthimia V.
        • Neokleous N.
        • Agapidou A.
        • Economou M.
        • Vetsiou E.
        • Teli A.
        • Perifanis V.
        Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
        Ann Hematol. 2013; 92: 263-265
        • Wong P.
        • Fuller P.J.
        • Gillespie M.T.
        • Kartsogiannis V.
        • Strauss B.J.G.
        • Bowden D.K.
        • et al.
        Thalassemia bone disease: The association between nephrolithiasis, bone mineral density and fractures.
        Osteoporos. Int. 2013; 24 ( 1965-1971
        • Sayani F.
        • Lal A.
        • Tasian G.
        • Mukaddam M.
        • Killilea D.
        • Fung E.
        Kidney stones in transfusion-dependent thalassemia: Prevalence and risk factors.
        Open Journal of Urology. 2022; 12: 209-227